Literature DB >> 26622342

Interleukin-17A promotes the formation of inflammation in the lung tissues of rats with pulmonary fibrosis.

Wei Ding1, Xing-Yi Zhang1, Ming Pan1, Bin Zhao1, Chuang Chen1, Zhi-Hao Niu1, Cheng-Liang Huang2, Yan-Yan Li2, Xian-Ming Fan2, Yan-Mei Ma2, Ming Zhang2, Wen-Jun Zhang2.   

Abstract

The aim of the present study was to investigate the effects of interleukin (IL)-17A in a rat model of pulmonary fibrosis. In total, 20 female Wistar rats were randomly divided into a normal saline (NS group) and a bleomycin group (BLM group). The BLM group rats were intratracheally instilled with BLM, while the NS group rats were intratracheally instilled with saline. In each group, half the rats were sacrificed at day 7 and day 28, respectively, following intratracheal instillation. Subsequently, hematoxylin and eosin and Masson's trichrome staining were performed to observe the pathological changes in the lung tissue, while the expression of IL-17A in the lung tissue was detected by immunohistochemistry. In addition, the bronchoalveolar lavage fluid (BALF) was collected and divided into two sections. One section was used for cell counting and classification, and an ELISA was performed to detect the concentration of IL-17A in the BALF. The additional section was used to separate, purify and cultivate alveolar macrophages (AMs). The concentration of IL-17A in the cultivating supernatant was detected by ELISA, and the mRNA expression levels of IL-17A in the AMs were detected using reverse transcription-polymerase chain reaction (RT-PCR). The results revealed that a considerable number of inflammatory cells had infiltrated into the alveolar cavity in the BLM group at day 7, and less alveolitis and more serious fibrosis were observed at day 28, as compared with the NS group. Furthermore, when compared with the NS group, the protein expression levels of IL-17A in the lung tissue were markedly higher in the BLM group at days 7 and 28 (higher at day 7; P<0.05). In addition, the total number of BALF cells in the BLM group was clearly higher at day 7 when compared with the NS group (P<0.05), although a normal level was re-established by day 28. The level of IL-17A in the BALF increased significantly at days 7 and 28 in the BLM group; however, when compared with the level at day 7, the concentration had decreased at day 28. When compared with the NS group, the protein expression levels of IL-17A in the BLM group were notably higher after 12, 24 and 48 h. In addition, the results of the RT-PCR assay revealed that the mRNA expression levels of IL-17A increased significantly at days 7 and 28 in the BLM group when compared with the NS group (P<0.05). Therefore, IL-17A was demonstrated to promote the development of pulmonary inflammation, which may be involved in the development of pulmonary fibrosis.

Entities:  

Keywords:  interleukin-17A; pulmonary fibrosis; pulmonary inflammation

Year:  2015        PMID: 26622342      PMCID: PMC4509370          DOI: 10.3892/etm.2015.2564

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  16 in total

1.  NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription.

Authors:  Kang-Yun Lee; Kazuhiro Ito; Ryuji Hayashi; Elen P I Jazrawi; Peter J Barnes; Ian M Adcock
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

2.  [Effects of combination of Salvia and Ligustrazine on TNF-α and TGF-β1 in serum and BALF of rats with pulmonary fibrosis].

Authors:  Chengliang Huang; Yanyan Li; Xianming Fan; Wenjun Wang; Xiaoqin Zhan
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2013-07

3.  New antibiotics, bleomycin A and B.

Authors:  H Umezawa; K Maeda; T Takeuchi; Y Okami
Journal:  J Antibiot (Tokyo)       Date:  1966-09       Impact factor: 2.649

4.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Authors:  Craig Leonardi; Robert Matheson; Claus Zachariae; Gregory Cameron; Linda Li; Emily Edson-Heredia; Daniel Braun; Subhashis Banerjee
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

5.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

6.  Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms.

Authors:  Su Mi; Zhe Li; Hong-Zhen Yang; Hong Liu; Jia-Ping Wang; Yong-Gang Ma; Xiao-Xing Wang; Han-Zhi Liu; Wei Sun; Zhuo-Wei Hu
Journal:  J Immunol       Date:  2011-08-12       Impact factor: 5.422

7.  Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent.

Authors:  Mark S Wilson; Satish K Madala; Thirumalai R Ramalingam; Bernadette R Gochuico; Ivan O Rosas; Allen W Cheever; Thomas A Wynn
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

8.  Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice.

Authors:  Tomoaki Hoshino; Masaki Okamoto; Yuki Sakazaki; Seiya Kato; Howard A Young; Hisamichi Aizawa
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-05       Impact factor: 6.914

9.  Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis.

Authors:  Ken-Ichiro Tanaka; Tomoaki Ishihara; Arata Azuma; Shoji Kudoh; Masahito Ebina; Toshihiro Nukiwa; Yukihiko Sugiyama; Yuichi Tasaka; Takushi Namba; Tsutomu Ishihara; Keizo Sato; Yutaka Mizushima; Tohru Mizushima
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-24       Impact factor: 5.464

Review 10.  IL-17 in the rheumatologist's line of sight.

Authors:  Marie-Elise Truchetet; M Djavad Mossalayi; Katia Boniface
Journal:  Biomed Res Int       Date:  2013-07-25       Impact factor: 3.411

View more
  6 in total

1.  Frequency of Th17 cells correlates with the presence of lung lesions in pigs chronically infected with Actinobacillus pleuropneumoniae.

Authors:  Elena L Sassu; Andrea Ladinig; Stephanie C Talker; Maria Stadler; Christian Knecht; Heiko Stein; Janna Frömbling; Barbara Richter; Joachim Spergser; Monika Ehling-Schulz; Robert Graage; Isabel Hennig-Pauka; Wilhelm Gerner
Journal:  Vet Res       Date:  2017-02-06       Impact factor: 3.683

Review 2.  The Role of Cytokines in the Fibrotic Responses in Crohn's Disease.

Authors:  Renata Curciarello; Guillermo H Docena; Thomas T MacDonald
Journal:  Front Med (Lausanne)       Date:  2017-08-07

3.  Cymbopogon winterianus Essential Oil Attenuates Bleomycin-Induced Pulmonary Fibrosis in a Murine Model.

Authors:  Lívia A Tavares; Allan A Rezende; Jymmys L Santos; Charles S Estevam; Ana M O Silva; Jaderson K Schneider; John L S Cunha; Daniela Droppa-Almeida; Ivan J Correia-Neto; Juliana C Cardoso; Patricia Severino; Eliana B Souto; Ricardo L C de Albuquerque-Júnior
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

4.  Clinical Role of Serum Interleukin-17A in the Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children.

Authors:  Jiuling Zhao; Xin Ji; Yushui Wang; Xin Wang
Journal:  Infect Drug Resist       Date:  2020-03-12       Impact factor: 4.003

5.  Bioinformatics Analysis Identifies Potential Ferroptosis Key Genes in the Pathogenesis of Pulmonary Fibrosis.

Authors:  Jie He; Xiaoyan Li; Mi Yu
Journal:  Front Genet       Date:  2022-01-06       Impact factor: 4.599

Review 6.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.